ORANGEBURG, N.Y., Oct. 28, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced that the Company will release its financial results for the second quarter of fiscal 2014, ended September 30, 2013, after the market closes on Monday, November 11, 2013. Howard Zauberman, Interim Chief Executive Officer, and Keith Darragh, VP, Finance, will host a conference call to discuss the results as follows:
|Date:||Tuesday, November 12, 2013|
|Time:||8:30 a.m. EST|
|Conference dial-in:||(877) 303-1595 U.S.|
|(970) 315-0449 International|
An audio replay of the conference call will be available from 11:30 a.m. EST on Tuesday, November 12, 2013, through 11:30 p.m. EST on Tuesday, November 19, 2013, by dialing (855) 859-2056 from the U.S. or (404) 537-3406 from abroad. The audio webcast will also be available in the investor section of the Company's website, www.visionsciences.com .
About Vision-Sciences, Inc.Vision-Sciences, Inc. designs, develops, manufactures and markets products for flexible endoscopy. The Company's unique product lines feature a streamlined visualization system and proprietary sterile disposable microbial barrier, known as EndoSheath ® technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. Information about Vision-Sciences' products is available at www.visionsciences.com . Vision-Sciences owns the trademarks Vision Sciences™ and Slide-On™ and the registered trademarks EndoSheath ®, EndoWipe ® and The Vision System ®.
CONTACT: Keith Darragh VP, Finance Vision-Sciences, Inc. (845) 848-1085 email@example.com Lisa Wilson President In-Site Communications, Inc. (212) 452-2793 firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts